Development of Anti-Human CC Chemokine Receptor 9 Monoclonal Antibodies for Flow Cytometry

Ren Nanamiya, Junko Takei, Teizo Asano, Tomohiro Tanaka, Masato Sano, Takuro Nakamura, Miyuki Yanaka, Hideki Hosono, Mika K. Kaneko, Yukinari Kato

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


CC chemokine receptor 9 (CCR9) belongs to the beta chemokine receptor family and is mainly distributed on the surface of immature T lymphocytes and enterocytes. This receptor is highly expressed in rheumatoid arthritis, colitis, type 2 diabetes, and various tumors. Therefore, more sensitive monoclonal antibodies (mAbs) need to be developed to predict the prognosis of many high CCR9 expression diseases. Because CCR9 is a structurally unstable G protein-coupled receptor, it has been difficult to develop anti-CCR9 mAbs using the traditional method. This study developed anti-human CCR9 (hCCR9) mAbs for flow cytometry using a Cell-Based Immunization and Screening (CBIS) method. Two mice were immunized with hCCR9-overexpressed Chinese hamster ovary (CHO)-K1 cells (CHO/hCCR9), and hybridomas showing strong signals from CHO/hCCR9 and no signals from CHO-K1 cells were selected by flow cytometry. We established an anti-hCCR9 mAb, C9Mab-1 (IgG1, kappa), which detected hCCR9 in MOLT-4 leukemia T lymphoblast cells and CHO/hCCR9 cells by flow cytometry. Our study showed that an anti-hCCR9 mAb was developed more rapidly by the CBIS method than the previous method.

Original languageEnglish
Pages (from-to)101-106
Number of pages6
JournalMonoclonal antibodies in immunodiagnosis and immunotherapy
Issue number3
Publication statusPublished - 2021 Jun


  • CBIS
  • CCR9
  • flow cytometry
  • monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Development of Anti-Human CC Chemokine Receptor 9 Monoclonal Antibodies for Flow Cytometry'. Together they form a unique fingerprint.

Cite this